Multidisciplinary meeting on male breast cancer: Summary and research recommendations

Journal of Clinical Oncology

Volumn 28, Issue 12, 2010, Pages 2114-2122

  Korde, Larissa A ^a   Zujewski, Jo Anne ^a   Kamin, Leah ^a   Giordano, Sharon ^a   Domchek, Susan ^a   Anderson, William F ^a   Bartlett, John M S ^a   Gelmon, Karen ^a   Nahleh, Zeina ^a   Bergh, Jonas ^a   Cutuli, Bruno ^a   Pruneri, Giancarlo ^a   McCaskill Stevens, Worta ^a   Gralow, Julie ^a   Hortobagyi, Gabriel ^a   Cardoso, Fatima ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; CYCLOPHOSPHAMIDE; ESTROGEN; FLUOROURACIL; GESTAGEN; GONADORELIN AGONIST; GOSERELIN; METHOTREXATE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER SURVIVAL; HUMAN; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; BREAST TUMOR; CONFERENCE PAPER; COOPERATION; GENETICS; INTERNATIONAL COOPERATION; MEDICAL RESEARCH; PRACTICE GUIDELINE; TREATMENT OUTCOME;

BIOMEDICAL RESEARCH; BREAST NEOPLASMS, MALE; COOPERATIVE BEHAVIOR; GUIDELINES AS TOPIC; HUMANS; INTERNATIONAL COOPERATION; MALE; RISK FACTORS; TREATMENT OUTCOME;

EID: 77951647826     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.5729     Document Type: Article

References (65)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2009. CA Cancer J Clin 59:225-249, 2009
2. Anderson WF, Chu KC, Chang S, et al: Comparison of age-specific incidence rate patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev 13:1128-1135, 2004 (Pubitemid 38917901)
3. Engholm G, Ferlay J, Christensen N, et al: NORDCAN: Cancer Incidence, Mortality and Prevalence in the Nordic Countries, Version 3.4, Association of Nordic Cancer Registries. Copenhagen, Denmark, Danish Cancer Society, 2009
4. Couch FJ, Farid LM, DeShano ML, et al: BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 13:123-125, 1996 (Pubitemid 126528243)
5. Haraldsson K, Loman N, Zhang QX, et al: BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease. Cancer Res 58:1367-1371, 1998 (Pubitemid 28193591)
6. Thorlacius S, Tryggvadottir L, Olafsdottir GH, et al: Linkage to BRCA2 region in hereditary male breast cancer. Lancet 346:544-545, 1995
7. Wooster R, Bignell G, Lancaster J, et al: Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789-792, 1995 (Pubitemid 26004412)
8. Brose MS, Rebbeck TR, Calzone KA, et al: Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94:1365-1372, 2002 (Pubitemid 35154141)
9. Anelli A, Anelli TF, Youngson B, et al: Mutations of the p53 gene in male breast cancer. Cancer 75:2233-2238, 1995
10. Fackenthal JD, Marsh DJ, Richardson AL, et al: Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet 38:159-164, 2001 (Pubitemid 32250866)
11. Meijers-Heijboer H, van den Ouweland A, Klijn J, et al: Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31:55-59, 2002
12. Evans DB, Crichlow RW: Carcinoma of the male breast and Klinefelter's syndrome: Is there an association? CA Cancer J Clin 37:246-251, 1987 (Pubitemid 17161782)
13. Hultborn R, Hanson C, Kopf I, et al: Prevalence of Klinefelter's syndrome in male breast cancer patients. Anticancer Res 17:4293-4297, 1997 (Pubitemid 28081702)
14. Cancer risks in BRCA2 mutation carriers: The Breast Cancer Linkage Consortium. J Natl Cancer Inst 91:1310-1316, 1999
15. Chodick G, Struewing JP, Ron E, et al: Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: Evidence from 261 cases in Israel, 1976-1999. Eur J Med Genet 51:141-147, 2008
16. Tai YC, Domchek S, Parmigiani G, et al: Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 99:1811-1814, 2007
17. Thompson D, Easton DF: Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94: 1358-1365, 2002 (Pubitemid 35154140)
18. Frank TS, Deffenbaugh AM, Reid JE, et al: Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: Analysis of 10,000 individuals. J Clin Oncol 20:1480-1490, 2002 (Pubitemid 34260526)
19. CHEK2 Breast Cancer Case-Control Consortium: CHEK2*1100delC and susceptibility to breast cancer: A collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 74:1175-1182, 2004
20. Vahteristo P, Bartkova J, Eerola H, et al: A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 71:432-438, 2002 (Pubitemid 34800260)
21. Anderson WF, Althuis MD, Brinton LA, et al: Is male breast cancer similar or different than female breast cancer? Breast Cancer Res Treat 83:77-86, 2004
22. Ron E, Ikeda T, Preston DL, et al: Male breast cancer incidence among atomic bomb survivors. J Natl Cancer Inst 97:603-605, 2005 (Pubitemid 40723788)
23. Sasco AJ, Lowenfels AB, Pasker-de Jong P: Review article: Epidemiology of male breast cancer - A meta-analysis of published case-control studies and discussion of selected aetiological factors. Int J Cancer 53:538-549, 1993 (Pubitemid 23069261)
24. Demers PA, Thomas DB, Rosenblatt KA, et al: Occupational exposure to electromagnetic fields and breast cancer in men. Am J Epidemiol 134:340-347, 1991
25. Hsing AW, McLaughlin JK, Cocco P, et al: Risk factors for male breast cancer (United States). Cancer Causes Control 9:269-275, 1998 (Pubitemid 28319019)
26. Sorensen HT, Friis S, Olsen JH, et al: Risk of liver and other types of cancer in patients with cirrhosis: A nationwide cohort study in Denmark. Hepatology 28:921-925, 1998 (Pubitemid 28450250)
27. Brinton LA, Richesson DA, Gierach GL, et al: Prospective evaluation of risk factors for male breast cancer. J Natl Cancer Inst 100:1477-1481, 2008
28. IMPACT Study: Homepage. http://www.impactstudy.co.uk/public/home
29. Adami HO, Holmberg L, Malker B, et al: Long-term survival in 406 males with breast cancer. Br J Cancer 52:99-103, 1985 (Pubitemid 15061106)
30. Cutuli B, Lacroze M, Dilhuydy JM, et al: Male breast cancer: Results of the treatments and prognostic factors in 397 cases. Eur J Cancer 31A:1960-1964, 1995
31. Donegan WL, Redlich PN, Lang PJ, et al: Carcinoma of the breast in males: A multiinstitutional survey. Cancer 83:498-509, 1998 (Pubitemid 28354506)
32. Goss PE, Reid C, Pintilie M, et al: Male breast carcinoma: A review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996. Cancer 85:629-639, 1999
33. Norris HJ, Taylor HB: Carcinoma of the male breast. Cancer 23:1428-1435, 1969
34. Ribeiro G: Male breast carcinoma: A review of 301 cases from the Christie Hospital & Holt Radium Institute, Manchester. Br J Cancer 51:115-119, 1985
35. Ribeiro GG: Carcinoma of the male breast: A review of 200 cases. Br J Surg 64:381-383, 1977
36. Scheike O: Male breast cancer: 6. Factors influencing prognosis. Br J Cancer 30:261-271, 1974
37. Stierer M, Rosen H, Weitensfelder W, et al: Male breast cancer: Austrian experience. World J Surg 19:687-692, 1995
38. van Geel AN, van Slooten EA, Mavrunac M, et al: A retrospective study of male breast cancer in Holland. Br J Surg 72:724-727, 1985 (Pubitemid 16215174)
39. Scott-Conner CE, Jochimsen PR, Menck HR, et al: An analysis of male and female breast cancer treatment and survival among demographically identical pairs of patients. Surgery 126:775-780, 1999
40. Giordano SH, Cohen DS, Buzdar AU, et al: Breast carcinoma in men: A population-based study. Cancer 101:51-57, 2004 (Pubitemid 38812422)
41. Crew KD, Neugut AI, Wang X, et al: Racial disparities in treatment and survival of male breast cancer. J Clin Oncol 25:1089-1098, 2007 (Pubitemid 46596761)
42. Wernberg JA, Yap J, Murekeyisoni C, et al: Multiple primary tumors in men with breast cancer diagnoses: A SEER database review. J Surg Oncol 99:16-19, 2009
43. Joshi A, Kapila K, Verma K: Fine needle aspiration cytology in the management of male breast masses: Nineteen years of experience. Acta Cytol 43:334-338, 1999 (Pubitemid 29239293)
44. Fentiman IS, Fourquet A, Hortobagyi GN: Male breast cancer. Lancet 367:595-604, 2006 (Pubitemid 43247575)
45. Curigliano G, Colleoni M, Renne G, et al: Recognizing features that are dissimilar in male and female breast cancer: Expression of p21Waf1 and p27Kip1 using an immunohistochemical assay. Ann Oncol 13:895-902, 2002 (Pubitemid 34752685)
46. Giordano SH, Buzdar AU, Hortobagyi GN: Breast cancer in men. Ann Intern Med 137:678-687, 2002 (Pubitemid 35176102)
47. Rayson D, Erlichman C, Suman VJ, et al: Molecular markers in male breast carcinoma. Cancer 83:1947-1955, 1998
48. Weber-Chappuis K, Bieri-Burger S, Hurlimann J: Comparison of prognostic markers detected by immunohistochemistry in male and female breast carcinomas. Eur J Cancer 32A:1686-1692, 1996 (Pubitemid 26306878)
49. Ellis P, Barrett-Lee P, Johnson L, et al: Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): An open-label, phase III, randomised controlled trial. Lancet 373:1681-1692, 2009
50. Bloom KJ, Govil H, Gattuso P, et al: Status of HER-2 in male and female breast carcinoma. Am J Surg 182:389-392, 2001 (Pubitemid 33079093)
51. Wang-Rodriguez J, Cross K, Gallagher S, et al: Male breast carcinoma: Correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases. Mod Pathol 15:853-861, 2002 (Pubitemid 34919778)
52. Ciocca V, Bombonati A, Gatalica Z, et al: Cytokeratin profiles of male breast cancers. Histopathology 49:365-370, 2006 (Pubitemid 44401543)
53. Shak S, Palmer G, Baehner FL, et al: Molecular characterization of male breast cancer by standard quantitative RT-PCR analysis: First large genomic study of 347 male breast cancers compared to 82,434 female breast cancers. J Clin Oncol 27:18s, 2009 (suppl 15S; abstr 549)
54. Cutuli B: Strategies in treating male breast cancer. Expert Opin Pharmacother 8:193-202, 2007
55. Nahleh ZA, Srikantiah R, Safa M, et al: Male breast cancer in the veterans affairs population: A comparative analysis. Cancer 109:1471-1477, 2007 (Pubitemid 46595680)
56. Salvadori B, Saccozzi R, Manzari A, et al: Prognosis of breast cancer in males: An analysis of 170 cases. Eur J Cancer 30A:930-935, 1994 (Pubitemid 24256237)
57. Gentilini O, Chagas E, Zurrida S, et al: Sentinel lymph node biopsy in male patients with early breast cancer. Oncologist 12:512-515, 2007 (Pubitemid 350012112)
58. Flynn LW, Park J, Patil SM, et al: Sentinel lymph node biopsy is successful and accurate in male breast carcinoma. J Am Coll Surg 206:616-621, 2008
59. Chakravarthy A, Kim CR: Post-mastectomy radiation in male breast cancer. Radiother Oncol 65:99-103, 2002 (Pubitemid 35346555)
60. Cutuli B, Le-Nir CC, Serin D, et al: Male breast cancer: Evolution of treatment and prognostic factors - Analysis of 489 cases. Crit Rev Oncol Hematol [epub ahead of print on May 11, 2009]
61. Giordano SH, Perkins GH, Broglio K, et al: Adjuvant systemic therapy for male breast carcinoma. Cancer 104:2359-2364, 2005 (Pubitemid 41691556)
62. Ribeiro G, Swindell R: Adjuvant tamoxifen for male breast cancer (MBC). Br J Cancer 65:252-254, 1992
63. Walshe JM, Berman AW, Vatas U, et al: A prospective study of adjuvant CMF in males with node positive breast cancer: 20-year follow-up. Breast Cancer Res Treat 103:177-183, 2007 (Pubitemid 46789139)
64. Czene K, Bergqvist J, Hall P, et al: How to treat male breast cancer. Breast 16:S147-S154, 2007 (suppl 2)
65. Giordano SH, Hortobagyi GN: Leuprolide acetate plus aromatase inhibition for male breast cancer. J Clin Oncol 24:e42-e43, 2006